NEW YORK, NY / ACCESSWIRE / June 10, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Dentsply Sirona Inc. (NASDAQ:XRAY)
This lawsuit is on behalf of all persons or entities that purchased Dentsply’s common stock between June 9, 2021, and May 9, 2022.
A class action has commenced on behalf of certain shareholders in Dentsply Sirona Inc. According to the filed complaint, defendants orchestrated a scheme to inflate Dentsply’s revenue and earnings by manipulating the Company’s accounting for a distributor rebate program so that senior executives would be eligible for significant cash and stock-based incentive compensation. In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the class period. As a result of defendants’ misrepresentations, Dentsply’s common stock traded at artificially inflated prices during the class period.
Shareholders may find more information at https://securitiesclasslaw.com/securities/dentsply-sirona-inc-loss-submission-form/?id=28403&from=1
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Investors Affected : December 30, 2019 – April 22, 2022
A class action has commenced on behalf of certain shareholders in Axsome Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=28403&from=1
IonQ, Inc. (NYSE:IONQ)
Investors Affected : March 30, 2021 – May 2, 2022
A class action has commenced on behalf of certain shareholders in IonQ, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company’s 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ’s quantum the computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ’s revenue was derived from improper roundtripping transactions with related parties; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were the materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/ionq-inc-loss-submission-form/?id=28403&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com:
https://www.accesswire.com/704675/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-XRAY-AXSM-and-IONQ
